Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition
share announcement

Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 8482

Special Issue Editors

Dr. Isaura Tavares

E-Mail Website
Guest Editor
1. Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2. Institute for Research and Innovation in Health—I3S, University of Porto, 4200-135 Porto, Portugal
Interests: mechanisms of pain modulation
Dr. Daniel Humberto Pozza

E-Mail Website
Guest Editor
1. Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2. Institute for Research and Innovation in Health—I3S, University of Porto, 4200-135 Porto, Portugal
Interests: pain; biomarkers; quantitative sensory tests; cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pain is a very complex and fascinating subject with three main components: physical, cognitive and emotional. These components are intrinsically connected, and their mutual influences may account for the individuality and subjectivity of pain responses.

Acute pain is usually an alert mechanism that protects the body from further tissue injury. On the other hand, chronic pain is considered a disease that is usually difficult to manage. Many chronic pain patients never achieve satisfactory pain relief. Despite the extensive investigation of pain treatment, there is still the need for research, namely in chronic pain prevention by establishing the mechanisms involved in the earlier phases of the disease. This may pass from the experimental setting to the clinical. For example, and with regard to the latter, proper postoperative pain prevention and adequate management starting in the preoperative period is imperative, and cancer management may lead to chronic pain, which is not usually prevented. Furthermore, a huge emphasis has been placed on the physical component of pain, whereas cognitive and emotional components of the pain experience are understudied, namely due to the challenges of animal pain models.

This Special Issue aims to provide the best up-to-date information on research related to prevention of chronic pain. Studies may include experimental and comprehensive reviews in this field and are expected to include the challenges related to animal research, genetic tests, novel biomarkers, predictive sensory testing, cognitive behavioral approaches for emotional component of pain, and individualization of pain patients.

Dr. Isaura Tavares
Dr. Daniel Humberto Pozza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pain pathophysiology
  • pain prevention
  • predictive sensory testing
  • pre- and postoperative chronic pain
  • new biomarkers in pain
  • pain management and novel treatments
  • preemptive analgesia
  • inflammatory pain

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 201 KiB  
Article
Orofacial Migraine and Neurovascular Orofacial Pain: Response to Treatment—A Pilot Study
by Rafael Benoliel, Yair Sharav, Shimrit Heiliczer and Yaron Haviv
Biomedicines 2025, 13(3), 714; https://doi.org/10.3390/biomedicines13030714 - 14 Mar 2025
Viewed by 379
Abstract
Introduction: The International Classification of Orofacial Pain (ICOP) recognizes orofacial migraine (OFM) and neurovascular orofacial pain (NVOP) as migraine-related entities affecting the facial and oral regions. The diagnostic features of OFM and NVOP indicate that there are many similarities between the two. However, [...] Read more.
Introduction: The International Classification of Orofacial Pain (ICOP) recognizes orofacial migraine (OFM) and neurovascular orofacial pain (NVOP) as migraine-related entities affecting the facial and oral regions. The diagnostic features of OFM and NVOP indicate that there are many similarities between the two. However, we recently demonstrated that NVOP and OFM are two distinct diagnostic entities, confirming the ICOP classification. It was the aim of the present study to examine whether OFM and NVOP differ in response to pharmacotherapy. Materials and Methods: The cohort was made up of 40 patients attending a tertiary orofacial pain clinic. When implementing ICOP criteria, an OFM diagnosis was made in 23 and an NVOP diagnosis in 17. Results: No statistically significant differences between NVOP versus OFM were observed in the global response to standard abortive therapy such as triptans, or NSAIDs. Similarly, no statistically significant differences were found following prophylactic therapy that included beta-blockers, anti-epileptic drugs, and tricyclic antidepressants. Up to 80% of patients responded favorably with ≥50% pain reduction. Conclusions: NVOP and OFM differ in diagnostic characteristics, demonstrating unique features, and were confirmed as two diagnostic entities. However, NVOP and OFM did not differ in their response to abortive or prophylactic treatments. Study limitations include the lack of starting data precluding a more precise pharmacological analysis. The small sample size limits any far reaching conclusions. This is particularly true regarding individual drug efficacy. We were unable to analyze drug and dose responses separately due to data constraints. Full article
(This article belongs to the Special Issue Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition)
12 pages, 552 KiB  
Article
Effectiveness of Generative Artificial Intelligence-Driven Responses to Patient Concerns in Long-Term Opioid Therapy: Cross-Model Assessment
by Giuliano Lo Bianco, Christopher L. Robinson, Francesco Paolo D’Angelo, Marco Cascella, Silvia Natoli, Emanuele Sinagra, Sebastiano Mercadante and Filippo Drago
Biomedicines 2025, 13(3), 636; https://doi.org/10.3390/biomedicines13030636 - 5 Mar 2025
Viewed by 752
Abstract
Background: While long-term opioid therapy is a widely utilized strategy for managing chronic pain, many patients have understandable questions and concerns regarding its safety, efficacy, and potential for dependency and addiction. Providing clear, accurate, and reliable information is essential for fostering patient understanding [...] Read more.
Background: While long-term opioid therapy is a widely utilized strategy for managing chronic pain, many patients have understandable questions and concerns regarding its safety, efficacy, and potential for dependency and addiction. Providing clear, accurate, and reliable information is essential for fostering patient understanding and acceptance. Generative artificial intelligence (AI) applications offer interesting avenues for delivering patient education in healthcare. This study evaluates the reliability, accuracy, and comprehensibility of ChatGPT’s responses to common patient inquiries about opioid long-term therapy. Methods: An expert panel selected thirteen frequently asked questions regarding long-term opioid therapy based on the authors’ clinical experience in managing chronic pain patients and a targeted review of patient education materials. Questions were prioritized based on prevalence in patient consultations, relevance to treatment decision-making, and the complexity of information typically required to address them comprehensively. We assessed comprehensibility by implementing the multimodal generative AI Copilot (Microsoft 365 Copilot Chat). Spanning three domains—pre-therapy, during therapy, and post-therapy—each question was submitted to GPT-4.0 with the prompt “If you were a physician, how would you answer a patient asking…”. Ten pain physicians and two non-healthcare professionals independently assessed the responses using a Likert scale to rate reliability (1–6 points), accuracy (1–3 points), and comprehensibility (1–3 points). Results: Overall, ChatGPT’s responses demonstrated high reliability (5.2 ± 0.6) and good comprehensibility (2.8 ± 0.2), with most answers meeting or exceeding predefined thresholds. Accuracy was moderate (2.7 ± 0.3), with lower performance on more technical topics like opioid tolerance and dependency management. Conclusions: While AI applications exhibit significant potential as a supplementary tool for patient education on opioid long-term therapy, limitations in addressing highly technical or context-specific queries underscore the need for ongoing refinement and domain-specific training. Integrating AI systems into clinical practice should involve collaboration between healthcare professionals and AI developers to ensure safe, personalized, and up-to-date patient education in chronic pain management. Full article
(This article belongs to the Special Issue Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition)
►▼ Show Figures

Figure 1

11 pages, 601 KiB  
Article
Predictive Model for Opioid Use Disorder in Chronic Pain: A Development and Validation Study
by Mónica Escorial, Javier Muriel, César Margarit, Laura Agulló, Thomas Zandonai, Ana Panadero, Domingo Morales and Ana M. Peiró
Biomedicines 2024, 12(9), 2056; https://doi.org/10.3390/biomedicines12092056 - 10 Sep 2024
Viewed by 1162
Abstract
Background/Objective: There are several questionnaires for the challenge of anticipating opioid use disorder (OUD). However, many are not specific for chronic non-cancer pain (CNCP) or have been developed in the American population, whose sociodemographic factors are very different from the Spanish population, leading [...] Read more.
Background/Objective: There are several questionnaires for the challenge of anticipating opioid use disorder (OUD). However, many are not specific for chronic non-cancer pain (CNCP) or have been developed in the American population, whose sociodemographic factors are very different from the Spanish population, leading to scarce translation into clinical practice. Thus, the aim of this study is to prospectively validate a predictive model for OUD in Spanish patients under long-term opioids. Methods: An innovative two-stage predictive model was developed from retrospective (n = 129) and non-overlapping prospective (n = 100) cohorts of real-world CNCP outpatients. All subjects used prescribed opioids for 6 or more months. Sociodemographic, clinical and pharmacological covariates were registered. Mu-opioid receptor 1 (OPRM1, A118G, rs1799971) and catechol-O-methyltransferase (COMT, G472A, rs4680) genetic variants plus cytochrome P450 2D6 (CYP2D6) liver enzyme phenotypes were also analyzed. The model performance and diagnostic accuracy were calculated. Results: The two-stage model comprised risk factors related to OUD (younger age, work disability and high daily opioid dose) and provided new useful information about other risk factors (low quality of life, OPRM-G allele and CYP2D6 extreme phenotypes). The validation showed a satisfactory accuracy (70% specificity and 75% sensitivity) for our predictive model with acceptable discrimination and goodness of fit. Conclusions: Our study presents the results of an innovative model for predicting OUD in our setting. After external validation, it could represent a change in the paradigm of opioid treatment, helping clinicians to better identify and manage the risks and reduce the side effects and complications. Full article
(This article belongs to the Special Issue Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition)
►▼ Show Figures

Figure 1

15 pages, 2171 KiB  
Article
Green Light Exposure Reduces Primary Hyperalgesia and Proinflammatory Cytokines in a Rodent Model of Knee Osteoarthritis: Shedding Light on Sex Differences
by Laura Ventura, Renan F. do Espírito-Santo, Michael Keaser, Youping Zhang, Jin Y. Ro and Joyce T. Da Silva
Biomedicines 2024, 12(9), 2005; https://doi.org/10.3390/biomedicines12092005 - 3 Sep 2024
Cited by 1 | Viewed by 1509
Abstract
Knee osteoarthritis (OA) often causes chronic pain that disproportionately affects females. Proinflammatory cytokines TNF-α, IL-1β, and IL-6 are key effectors of OA pathological changes. Green light shows potential as an alternative intervention for various pain conditions. However, no studies have investigated green light′s [...] Read more.
Knee osteoarthritis (OA) often causes chronic pain that disproportionately affects females. Proinflammatory cytokines TNF-α, IL-1β, and IL-6 are key effectors of OA pathological changes. Green light shows potential as an alternative intervention for various pain conditions. However, no studies have investigated green light′s analgesic effects in both sexes in chronic knee OA. We induced unilateral knee OA with intra-articular injection of monoiodoacetate (MIA) in male and female Sprague-Dawley rats. Two days post-injection, the rats were exposed to green-light-emitting diodes (GLED) or ambient room light eight hours daily for 24 days. Knee mechanical sensitivity was assessed using a small animal algometer. Blood serum concentrations of TNF-α, IL-1β, IL-6, and IL-10 were quantified at baseline and 23 days post-injection. MIA injection decreased the knee mechanical thresholds of the male and female rats. GLED exposure attenuated mechanical hypersensitivity in both sexes compared to the controls; however, GLED-induced analgesia occurred sooner and with greater magnitude in males than in females. In both sexes, the analgesic effects of green light lasted 5 days after the final GLED session. Finally, GLED exposure reversed the elevation of serum proinflammatory cytokines. These findings suggest that GLED exposure reduces primary hyperalgesia in OA, potentially by lowering proinflammatory cytokines, and indicate sex differences in GLED-induced analgesia. Full article
(This article belongs to the Special Issue Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition)
►▼ Show Figures

Figure 1

7 pages, 393 KiB  
Communication
Rikkosan’s Short-Term Analgesic Effect on Burning Mouth Syndrome: A Single-Arm Cohort Study
by Tatsuki Itagaki, Keisuke Nakamura, Tougo Tanabe, Takumi Shimura, Yu Nakai, Ken-ichiro Sakata, Jun Sato and Yoshimasa Kitagawa
Biomedicines 2024, 12(5), 1013; https://doi.org/10.3390/biomedicines12051013 - 4 May 2024
Viewed by 1731
Abstract
Burning mouth syndrome (BMS) is a chronic oral pain disorder. There is a theory that BMS is a form of nociplastic pain. A standard treatment for BMS has not yet been established. Kampo medicine is a traditional oriental medicine. The purpose of this [...] Read more.
Burning mouth syndrome (BMS) is a chronic oral pain disorder. There is a theory that BMS is a form of nociplastic pain. A standard treatment for BMS has not yet been established. Kampo medicine is a traditional oriental medicine. The purpose of this study is to evaluate the effectiveness of Rikkosan—a traditional Japanese herbal medicine (Kampo)—in the treatment of BMS. A single-center retrospective study was conducted on 20 patients who were diagnosed with BMS and treated with Rikkosan alone (total daily dose; 7.5 g) three times daily for approximately 4 weeks (29.5 ± 6.5 days). Rikkosan was dissolved in hot water and taken internally. They had an average age of 63 years, and 90% were being treated for other illnesses, but their medication status was the same during this study period, except for Rikkosan. No adverse events were observed in patients. Numerical rating scale (NRS) or visual analog scale (VAS)/10 scores decreased significantly between the time of the initiation of Rikkosan and one month after (−2.1 ± 1.2, p < 0.05). Rikkosan has a short-term effect of reducing NRS by two levels in BMS patients. Full article
(This article belongs to the Special Issue Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 232 KiB  
Review
Basivertebral Nerve Ablation for Treatment of Lower Back Pain
by Esther Lee, Joaane Kim, Sadiq Rahman, Neil Daksla, William Caldwell and Sergio Bergese
Biomedicines 2024, 12(9), 2046; https://doi.org/10.3390/biomedicines12092046 - 9 Sep 2024
Viewed by 1914
Abstract
Lower back pain (LBP) is a widely prevalent global health issue, affecting over half a billion people and remaining the leading cause of years lived with disability (YLDs). LBP significantly impacts healthcare systems, with substantial costs related to surgical procedures and lost workdays. [...] Read more.
Lower back pain (LBP) is a widely prevalent global health issue, affecting over half a billion people and remaining the leading cause of years lived with disability (YLDs). LBP significantly impacts healthcare systems, with substantial costs related to surgical procedures and lost workdays. Vertebrogenic back pain (VBP), characterized by specific clinical symptoms and associated with Modic changes (MC) in vertebral endplates, best seen on MRI, is a significant subset of LBP. This paper explores the pathophysiology, diagnosis, and current reports and studies focusing on VBP and the role of basivertebral nerve (BVN) ablation as a therapeutic intervention. Multiple studies, including randomized controlled trials (RCTs) and meta-analyses, demonstrate the efficacy of BVN ablation in reducing pain and improving function in patients with chronic LBP associated with MC. Full article
(This article belongs to the Special Issue Chronic Pain: From Prevention to Therapeutic Strategies—Second Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop